Chemed is being priced off a two‑year growth burst, even though revenue slowed to 4.1% last year

Chemed’s shares sit near $534.89 after a six‑month climb of 23.7%.

The reason is simple on paper: revenue sits at $2.5B for 2025, up only +4.1% year over year after an outsized jump in 2023. That 2023 spike, revenue +88.5% year over year, still dominates the company’s recent history and shapes how scenarios are being built.